Daratumumab (Darzalex) ELISA Kit

Daratumumab is a monoclonal antibody used primarily for the treatment of multiple myeloma, a type of blood cancer. It works by targeting CD38, a surface protein expressed on the surface of myeloma cells, which plays a critical role in cell survival and proliferation. By binding to CD38, Daratumumab induces the destruction of myeloma cells through various mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis. This therapeutic approach has shown significant efficacy in treating multiple myeloma, especially when combined with other drugs, and is used in both newly diagnosed and relapsed or refractory cases.

The Daratumumab (Darzalex) ELISA Kit is an essential tool for accurately measuring Daratumumab concentrations in patient serum or plasma samples. This immunological test provides a highly reliable method for monitoring drug levels, ensuring that patients receive the optimal therapeutic dose. The ELISA kit is designed to be precise and sensitive, capable of detecting even low levels of Daratumumab, which is crucial for assessing treatment adherence and therapy effectiveness over time.

In clinical settings, the Daratumumab ELISA Kit plays an important role in therapeutic monitoring. By tracking the concentration of Daratumumab in the bloodstream, healthcare providers can ensure that patients are receiving the appropriate dosage. This kit is also invaluable in pharmacokinetic studies, helping researchers understand how the drug is absorbed, distributed, metabolized, and eliminated in the body. Additionally, the ELISA kit can aid in detecting adverse effects related to insufficient or excessive drug levels, ensuring the safety and efficacy of the treatment.

For researchers and clinical laboratories, the Daratumumab (Darzalex) ELISA Kit is an indispensable tool that facilitates a wide range of studies, from treatment monitoring to pharmacokinetics and bioavailability assessments. This ensures a comprehensive understanding of Daratumumab’s pharmacological profile, leading to better patient outcomes and advancing the field of multiple myeloma treatment.

1. Therapeutic Monitoring: The Daratumumab (Darzalex) ELISA Kit allows healthcare providers to monitor the drug levels in patients undergoing Daratumumab therapy. By assessing the concentration of the drug in serum or plasma samples, clinicians can ensure that patients are receiving the correct dose, enabling optimal therapeutic effects. This monitoring is critical for adjusting doses and preventing under- or over-treatment, improving patient outcomes during therapy.

2. Pharmacokinetic Studies: The Daratumumab ELISA Kit is also an invaluable tool in pharmacokinetic studies. It aids researchers in understanding how Daratumumab behaves within the body, including its absorption, distribution, metabolism, and elimination. By analyzing these factors, the pharmacokinetic profile of Daratumumab can be better understood, which is essential for determining the most effective dosing schedules and improving therapeutic strategies.

3. Adverse Effect Monitoring: Accurate monitoring of Daratumumab levels is essential for detecting potential adverse effects. By maintaining proper drug concentrations, clinicians can prevent or manage side effects associated with both insufficient and excessive drug levels. This includes monitoring for potential immune responses or other adverse reactions, ensuring the safety and well-being of patients undergoing Daratumumab therapy.

4. Bioavailability and Bioequivalence Studies: The ELISA kit can also be used to evaluate the bioavailability and bioequivalence of Daratumumab formulations or biosimilars. By comparing the absorption and effectiveness of different formulations, researchers can assess the therapeutic equivalence of alternative versions of Daratumumab, ensuring that patients receive the same quality of care and therapeutic benefits, regardless of the specific formulation.

1. High Sensitivity: The Daratumumab (Darzalex) ELISA Kit offers exceptional sensitivity, capable of detecting even the lowest levels of Daratumumab in serum or plasma samples. This ensures accurate results for patients with varying drug concentrations, including those with low drug levels due to pharmacokinetic factors or those in the early stages of treatment. High sensitivity is crucial for monitoring patient compliance and therapy effectiveness.

2. Quick and Easy Application: The kit is designed with a simple and efficient protocol, allowing healthcare providers and researchers to obtain reliable results quickly. Its user-friendly steps streamline the testing process, making it easy to use in both clinical and laboratory settings. This reduces the time required to monitor Daratumumab levels, enabling faster decision-making and better patient management.

3. Specificity: The Daratumumab ELISA Kit utilizes highly specific antibodies that target Daratumumab with precision, minimizing the risk of false positives. This high specificity ensures that the test is not affected by other similar substances in the sample, providing more accurate and reliable results. It is an essential feature for clinical studies and therapeutic monitoring, where precision is key to successful treatment outcomes.

4. Wide Dynamic Range: The ELISA Kit delivers accurate and precise measurements across a broad concentration range of Daratumumab. This wide dynamic range ensures that the kit is suitable for a diverse range of patient samples, from those with high drug concentrations to those with very low levels of the drug. This feature enhances the robustness of the test and its applicability in various clinical scenarios.

96 well plates are coated with CD38 antigen to capture Daratumumab from the sample, ensuring specific binding and accurate detection.

Sensitivity: 98.5%

Specificity: 99%

SC-DAR-001